Literature DB >> 11906779

DTPw-HB and Hib primary and booster vaccination: combined versus separate administration to Latin American children.

José Ignacio Santos1, Amando Martin, Tirza De Leon, Luis Rivera, Maria Elisa García Gaitán, Carlos Del Rio, Gabriel Oselka, Yolanda Cervantes, Pilar Rubio, Sue Ann Costa Clemens, João Silva de Mendonça.   

Abstract

This multicentre study was designed to establish the reactogenicity and immunogenicity profiles of primary and booster vaccination with diphtheria, tetanus, and pertussis whole-cell-hepatitis B/Haemophilus influenzae type-b (DTPw-HB/Hib) administered as either a syringe mix or as separate injections in 400 Latin American children. Both vaccine regimens were equally well tolerated and elicited post-primary excellent seropositivity rates at or close to 100% for all five component antigens. With regard to HB, 100% of subjects in the combined vaccination group, and 98.8% subjects in the separate injection vaccination group reached seroprotective antibody concentrations (>or=10 mIU/ml) 1 month after the primary vaccination course. Equally high anti-PRP antibody concentrations were reached 1 month after vaccination, with 100% of seroprotected subjects in the combined vaccination group (antibody concentrations >or=0.15 microg/ml), against 99.4% in the separate injection vaccination group. Seroprotective anti-HBs and anti-PRP antibody concentration levels persisted approximately 1 year after the primary vaccination course, just prior to booster vaccination. Finally, a significant increase of all antibody concentrations could be observed after the booster vaccination, since all but one subject in the separate injection vaccination group had protective levels of anti-HBs and anti-PRP antibodies 1 month after the booster dose. These results suggest that the combination of DTPw-HB and Hib vaccines provides an effective means for increasing vaccine coverage in childhood vaccination programmes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11906779     DOI: 10.1016/s0264-410x(01)00512-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Development of newborn and infant vaccines.

Authors:  Guzman Sanchez-Schmitz; Ofer Levy
Journal:  Sci Transl Med       Date:  2011-07-06       Impact factor: 17.956

2.  Safety monitoring of a new pentavalent vaccine in the expanded programme on immunisation in Ghana.

Authors:  Alexander N O Dodoo; Lorna Renner; Adrianus C van Grootheest; Jerry Labadie; Kwadwo O Antwi-Agyei; Selasie Hayibor; Johannes Addison; Victoria Pappoe; Augustina Appiah-Danquah
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

3.  Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination: a randomized controlled trial.

Authors:  Felix Espinoza; Miguel Tregnaghi; Angela Gentile; Katia Abarca; Javier Casellas; Alix Collard; Inge Lefevre; Jeanne-Marie Jacquet
Journal:  BMC Infect Dis       Date:  2010-10-15       Impact factor: 3.090

4.  High prevalence of occult hepatitis B virus genotype H infection among children with clinical hepatitis in west Mexico.

Authors:  Griselda Escobedo-Melendez; Arturo Panduro; Nora A Fierro; Sonia Roman
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-08-05       Impact factor: 2.743

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.